^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Anti-CD19/CD20/CD22 CAR T-Cells
i
Other names: Anti-CD19/CD20/CD22 CAR T-Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
